Guardant Health, IPS Genomix Collaborate
News Sep 20, 2016
Guardant Health has announced that it has inked an agreement with IPS Genomix to make its Guardant360 liquid biopsy test available to oncologists and their patients in the Middle East. Guardant Health Co-founder and CEO Helmy Eltoukhy said in a statement that the distribution deal grants patients across the United Arab Emirates, Saudi Arabia, Qatar, Kuwait, Oman, Lebanon, Egypt, and Jordan access to the targeted sequencing-based assay.
Guardant360 analyzes DNA fragments shed from solid tumors into the blood of cancer patients, in order to detect various classes of somatic genomic alterations in 70 genes with relevance to specific targeted therapies, or other aspects of clinical cancer management.
Under the terms of the new agreement, IPS Genomix will facilitate patient access to Guardant360, and will handle distribution and reimbursement for the test in the region. Guardant Health will still perform all sequencing, computation, and other analyses at its CLIA lab in Redwood City, California.
Guardant signed another similar international distribution deal with Teva Pharmaceuticals subsidiary Oncotest-Teva earlier this year, making Guardant360 available to patients with advanced cancer in Israel.
Penn Medicine Biochemist Receives Major Award for Research on Epigenetic Protein Modifications via Mass SpecNews
Benjamin A.Garcia, PhD, an expert in quantitative proteomics and Presidential Professor of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, has been awarded the Biemann Medal by the American Society for Mass Spectrometry (ASMS). The early-career award recognizes significant achievement in basic or applied mass spectrometry.
Targeting Epigenetic Proteins to Prevent Breast CancerNews
Researchers have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study suggests that inhibiting these proteins with drugs could prevent the development of breast cancer in women at high risk of the disease.READ MORE
Targeting the Engine Room of the Cancer CellNews
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.READ MORE